GRM5 and fragile X syndrome: ,8,9 Clinical trials, however, with two different mGluR5 inhibitors (basimglurant and mavoglurant) showed no therapeutic benefit in patients with FXS for reasons as yet unclear,10 prompting us to investigate further the importance of the mGluR5 signaling pathway in this syndrome.